A new class of diabetes drugs called SGLT-2 inhibitors -- which block the natural reabsorption of excess glucose in the bloodstream and allow it to pass out of the body -- could potentially be huge in the type 2 diabetes space, and Johnson & Johnson (NYSE:JNJ) recently received a 10-5 recommendation for approval for its SGLT-2 inhibitor Invokana from an FDA advisory committee. If approved, JNJ would be the first to market in the United States with this type of drug, which could be a nice win for the company.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 57% 37%
17+ years 350% 94%
Stock Advisor launched in February of 2002. Returns as of 12/07/2019.Join Stock Advisor
- 3 Warren Buffett Dividend Stocks You Can Buy Right Now
- Dow Jones News: Johnson & Johnson Concludes Asbestos Investigation; Analyst Sees Upside for United Technologies
- 3 Warren Buffett Stocks to Buy in December
- Should Investors Worry About Johnson & Johnson's Eroding Moat?
- 5 Top Dividend Stocks Investors Should Never Sell